United Bank (Virginia)’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

United Bank (Virginia)’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-37,400	Closed	-$7K	–	170
2022 Q3	$7K	Buy	37,400 +10,500	+39%	+$10.7K	﹤0.01%	157
2022 Q2	$16K	Hold	26,900	–	–	﹤0.01%	146
2022 Q1	$36K	Buy	+26,900	New	+$43.6K	﹤0.01%	158

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

United Bank (Virginia)'s PHAS Position: Q4 2022 in Review

United Bank (Virginia) sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 37,400 shares — an estimated $7K sold.

United Bank (Virginia) first reported a position in PHAS in Q1 2022 and held it in 3 quarters. The position peaked at $36K in Q1 2022. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

United Bank (Virginia) reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
United Bank (Virginia) sold 37,400 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $7K.
United Bank (Virginia) first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
United Bank (Virginia)'s PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $36K in Q1 2022.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on United Bank (Virginia)'s 13F filing for Q4 2022, filed 14 Feb 2023.